TLR9 and neoplasm: Unmethylated CpG ODN1826, a TLR9 agonist, has been shown to affect tumor growth in TC-1- and TC-1/A9-induced tumors [50] and has also been demonstrated to be an effective adjuvant for DNA immunization in the TC-1 tumor model [51].